Orchard Therapeutics Expands US Presence with New Corporate Office in Boston

April 25, 2018

BOSTON and LONDON, April 24, 2018 —Orchard Therapeutics, a leading commercial and clinical-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced the opening of a new U.S. office in Boston's Seaport District.

The new Boston office builds upon the company's footprint in London as well as Foster City and Menlo Park, California. Orchard's Boston office will become the company's hub for its commercial operations and several key financial and administrative functions to support the rapidly expanding global organization.

"The opening of our Boston office represents a significant milestone in the growth and global expansion of Orchard Therapeutics" commented Mark Rothera, president and CEO of Orchard. "We look forward to joining the thriving biotechnology and academic communities in Boston, Cambridge and the surrounding area. The area has a deep pool of talent with complementary capabilities to help us realize our vision of becoming a global, fully integrated company transforming the lives of patients with rare diseases."

Orchard's portfolio of autologous *ex vivo* gene therapy programs has demonstrated sustained clinical benefit (between two to 17 years) in over 120 patients across five disease areas. These programs include Strimvelis, the first autologous *ex vivo* gene therapy approved by the EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.

The company's most-advanced development candidate OTL-101 for ADA-SCID, is expected to progress to a BLA (biological license application) with the FDA in 2018.

About Orchard

Orchard Therapeutics is a leading global fully integrated commercial and clinical-stage company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.

Orchard's portfolio of autologous *ex vivo* gene therapy programs has demonstrated sustained clinical benefit in over 120 patients across five disease areas. These programs include Strimvelis, the first autologous *ex vivo* gene therapy approved by EMA in 2016, 3 programs in advanced registrational studies in MLD (metachromatic leukodystrophy), WAS (Wiskott Aldrich syndrome) and ADA-SCID (adenosine deaminase severe combined immunodeficiency), other clinical programs in X-CGD (X-linked chronic granulomatous disease) and beta-thalassemia, as well as an extensive preclinical pipeline.

The company is partnered with world-leading institutions in gene therapy, including University College London, Great Ormond Street Hospital, the University of Manchester and Central Manchester University Hospitals, the University of California Los Angeles, Boston Children's Hospital, and Telethon Institute for Gene Therapy/Ospedale San Raffaele.

Orchard is privately held with offices in the UK and the US, including London, San Francisco and Boston. The company raised $110 million in a Series B in December 2017, was named a Fierce 15 Company by FierceBiotech in 2016 and was awarded a $19 million grant from the California Institute of Regenerative Medicine (CIRM).

For further information please visit www.orchard-tx.com

Contacts

Corporate contact

Mary D. Wallace
Orchard Therapeutics
781-608-3666
Mary.Wallace@orchard-tx.com

Media contact

Allison Blum, Ph.D.
LifeSci Public Relations
+1 516 655 0842

Allison@lifescipublicrelations.com